April – 2019 – StemCell Therapy

What is Stem Cell Therapy – Stem Cell Centers

♫ Sunday, April 14th, 2019

What is Stem Cell Therapy?

The International Society for Stem Cell Research describes stem cells as the foundation cells of our body. Stem cells represent the sites where your organs and tissues started. Stem cells are recruited every day of your life to help repair and replace damaged tissues and cells. Stem cells are found in all of us and play a key role in the bodys healing process. They lie latent in your body until they receive signals that the body has suffered an injury and then they follow your platelets to the injured site. Stem cells are able to transform into the same type of cell that was injured to promote healing. They are tasked to heal injured ligaments, tendons, tissues and bones. Are you suffering from an injury and curious to know how stem cell therapy can help you heal? Scheduling a free consultation can help you learn how you can benefit from this curative approach to healing and injury repair.

Stem cells are not like the other cells in your body. They garnish more attention than average cells because of their unique abilities. Stem cells are divided into two classes: pluripotent and multipotent. Pluripotent stem cells can create any type of cell in the body except those needed to support and develop a fetus in the womb. Multipotent stem cells are restricted to becoming only a small number of different cell types. Stem cells can divide and renew themselves for long periods, they are dynamic in their ability to differentiate, and they can create specialized cell types. This ability stem cells have to self-renew and to differentiate is what sets them apart from the rest. Self-renewing stem cells are able to divide and regenerate more stem cells. Differentiating stem cells can transform into the specialized, mature cells that your tissues and organs need. Stem cells are divided into several different classifications:

Stem cells represent cutting-edge science. Stem cells give new hope to thousands of people with chronic medical conditions. Stem cell therapy has the potential to cure many diseases and conditions. Specialized stem cells have been shown to help treat serious medical conditions from cancer to birth defects. Stem cell research can help us gain ground on discovering how these conditions begin in the first place. Stem cells are also helpful for making cells and tissues for medical therapies. Pluripotent stem cells offer a renewable source of replacement cells and tissues for treating a variety of diseases, conditions, and disabilities such as Parkinsons disease, spinal cord injury, burns, heart disease, diabetes, and arthritis.

While ethical debates have arisen about embryonic stem cell therapy, most everyone agrees that the use of other Stem Cell Therapy raises no ethical or moral questions. Cord-Blood Stem Cell therapy also has an advantage over other methods because these stem cells carry no threat of patient rejection. The stem cells are neutral cells which have no DNA in them making everyone a match.

Stem cell donors go through a rigorous screening process, as determined by the Food and Drug Administration (FDA) and American Association of Tissue Banks (AATB). We couple the treatment with rehabilitation (if needed) provided by our integrated team, to correct the reason your injury occurred in the first place. Similar to cortisone and steroid shots, stem-cell injections have anti-inflammatory properties but offer far more benefits than those of standard injection therapies. While cortisone and other drugs only provide temporary pain relief, stem cells actually restore degenerated tissue while providing pain relief. The growth factors in Stem Cells may replace damaged cells in your body. Additionally, stem cell injections contain hyaluronic acid, which lubricates joints and tendons, easing the pain and helping restore mobility.

Regenerative medicine targets the bodys innate ability to heal and defend. Regenerative medicine helps to harness that power the body has to heal and then accelerate it and/or distribute it in ways that help the body recover better from injury and disease. One of the goals of regenerative medicine is to restore the structure and function of damaged organs and tissues to find cures for injuries and diseases that have been incurable in the past. Regenerative medicine targets the following key areas:

Stem cell research and therapies represent an exciting time for medical advancement and recovery from injuries and disease like never before. Regenerative medicine is exciting because of its potential to cure failing and impaired tissues. The medical advances of regenerative medicine are just beginning to be discovered. Stem cell therapies and regenerative medicine benefits are here to stay! Call for your free consultation today!

Here is the original post:
What is Stem Cell Therapy - Stem Cell Centers

♫ Posted in Stem Cell Therapy | | Comments Off»

Personalized Medicine Conferences 2019 | New Zealand 2019 …

♫ Sunday, April 14th, 2019

Sessions/Tracks

Track 1: Precision Medicine

The concept of precision medicine, in which health care is individually customized on the basis of a person's genes, lifestyle and environment. Transfusion patients have been matched with donors according to blood type for more than a century. But advances in genetics, and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 2: Precision Medicine and Novel Technology

Precision medicine aims to provide the right treatment for the right patient at the right time with treatment directed on the basis of the targetable tumoral aberrations rather than just a traditional histologic subtype. However to facilitate this approach, clinicians require patient derived samples. Prostate cancer is challenging to culturein vitro. Recent development of novel organoidin vitroculture technology has led to the development of multiple newin vitroprostate cancer cell line models. We aim to apply organoid culture technology to develop novelin vitroprostate cancer cell line models and propagate patient derived samples to allow drug testing and next generation sequencing as part of a precision medicine approach to early recurrent prostate cancer.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 3: Future of personalized medicine

Personalized Medicine Meetingis to develop a routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of the ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in the treatment of HIV, Applications of a customized drug in uncommon illnesses, Translational Medicine.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 4: Individualized Treatment through Personalized Medicine

Personalised medicine turns this approach on its head. It recognizes that complex diseases should no longer be considered as a single entity. One disease may have many different forms, or subtypes, resulting from the complex interaction of our biological make-up and the diverse pathological and physiological processes in our bodies. These will not only vary between patients who have the same disease but also within an individual patient as they get older and their body changes. As we integrate and analyses genomic and other data, we can find common factors and causes of variation, resulting in the discovery of new pathways of disease, changing how diseases are thought of and treated. It enables us to recognize that the same underlying change in our DNA or genome can lead to problems in very different parts of the body, which would not have been previously identified with a more traditional care approach.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 5: Precision Pathology

The role of predictive pathology or the accurate assessment of morphology at the microscopic level. In breast cancer, this has been most useful where histologic attributes such as the classification of tubular and cribriform carcinoma dictates surgery while neoadjuvant studies suggest that patients with lobular carcinoma are not likely to benefit from chemotherapy. The next level of 'personalized pathology' at the tissue-cellular level is the use of 'protein biomarker panels' to classify the disease process and ultimately drive tumor characterization and treatment. Precision pathology will focus on the evolution of predictive pathology from a subjective, 'opinion-based' approach to a quantitative science. The individual components of the precise pathology platform including advanced image analysis, biomarker quantitation with mathematical modeling and the integration with fluid-based (i.e. blood, urine) analytics as drivers of next generation precise patient phenotyping.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 6: Predictive Biomarkers

In drug, abiomarkerand sub-nuclear markers is the quantifiable pointer of the reality or region of some disease state. All the more overall itis anything that can be used as a marker of a particular illness state or some other physiological state of a living being Medication Symptomatic Co-Improvement. In the present time of stratified arrangement andbiomarker-driven medications, the inside has moved from figures considering the customary anatomic orchestrating systems to coordinate the choice of treatment for an individual patient to a planned strategy using the inherited beautifiers of the tumor and the genotype of the patient.Genomicsand different developments have, all things considered, Personalized Medicine Congress 2018 added to the unmistakable verification and the change ofbiomarkers, for example, Stratification biomarkers in modified pharmaceutical.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 7: Precision Medicine: Oncology

Precision Medicine in Oncology is doled out to illuminating, instructing, and encouraging the trading of clinically pertinent data with respect to the disclosure and utilization of new Drug regimens, Molecular biomarkers, Cancer genomics, Molecular growth and Diagnostics in strong tumors and hematologic malignancies, and in addition their effect on oncology watch over patients. Over late decades Cancer investigate has found an incredible and personalized medication to tumor research and treatment.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 8: Data science to advance precision medicine

Healthcare and medical research are generating more and more complex data, encompassing clinical investigations, genomic medicine, imaging, pharmacokinetics, metabolomics, epidemiology and beyond. This Data Science can form the basis for precision medicine, approaching disease prevention and treatment by taking into account individual variability in genes, environment, and lifestyle. By deeply profiling individual patients and using this to improve predictive models of pathology in individual patients, advances will be made in elucidating of the drivers of the disease and making precise targeted treatments, providing the right treatment to the right patient at the right time. Both biologists and clinicians need to understand this emerging and highly translational approach.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 9: Preventive Medicines

Preventive Medicine is sharpened by all specialists to keep their patients sound. It is also an extraordinary therapeutic distinguishing strength saw by the American Board of Medical Specialties (ABMS). Preventive Medicine focuses on the prosperity of individuals, gatherings, and portrayed peoples. It is similarly used for the treatment for strength, visual hindrance. The Epidemiology Division applies inquire about systems to fathom the illustrations and explanations behind prosperity and affliction in the people and to make a translation of this learning into ventures proposed to turn away disease. The division has a long history of consideration in NIH-bolstered multi-site, longitudinal accomplice studies, and its staff deal with various pro began, NIH-upheld investigation endeavors and trials. Open trust in antibodies is a key to the accomplishment of immunization ventures worldwide in the time of preventive solution.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 10: Cardiovascular medicine

The goal of the Personalized Medicine in cardiac research is to stimulate understanding of promising new essential examination disclosures for the treatment of heart disillusionment and arrhythmias through especially formed clinical trials that display suitability and security. Vascular Medicine encompasses an extensive variety of various sickness states. As the field of vascular Medicine builds up, the degree of ailments being managed changes. Cardiovascular revamping suggests the changes in estimate, shape, structure and physiology of the heart after harm to the myocardium. The mischief is regularly a direct result of extraordinary myocardial dead tissue. To depict the development in lipoprotein translation by hypothyroidism, adipocytes were prepared from control and hypothyroid rats. While LPL mix was higher in hypothyroid adipocytes, with no modification in mRNA levels, there was no extension in hormone-delicate lipase (HSL) mix.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 11: Precision Immunotherapy

Immunotherapy is a type of treatment that helps the bodys immune system fight cancer. Several kinds of immunotherapy, including immune checkpoint inhibitors, adoptive cell transfer, and therapeutic vaccines are either commercially available or in clinical development. To date, six immune checkpoint inhibitors have been approved by FDA for the treatment of eight types of cancer. One of the inhibitors has also been approved to treat any solid tumor that has a specific genetic feature. This was the first FDA approval of its kind and a major advance for precision cancer medicine, in which the molecular characteristics of a tumor are used to identify effective therapies.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 12: Pharmacogenomics & Personalized Medicine

Pharmacogenomics is a control in innate qualities that applies Recombinant DNA, DNA sequencing strategies, and bioinformatics to gathering, store up, and separate the limit and structure of genomes. Drives in genomics have set off an insurrection in exposure based examination to see even the most complex natural systems, for instance, the psyche. The field fuses attempts to choose the entire DNA gathering and human genome variety of living things and fine-scale inherited mapping. The field furthermore consolidates examinations of intragenomic wonders, for instance, heterosis, epistasis, pleiotropic and distinctive relationship amidst loci and all inside the genome and met genomics. Close genomics is an invigorating new field of regular investigation in which the genome groupings of different species human, mouse and a wide variety of various life frames from yeast to chimpanzees are contemplated.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 13: Approaches to Stem Cells and Cell therapy

Personalized Medicine can be used to discover around a man's genetic beauty care products and to unravel the study of their tumor. Using this information, experts need to perceive reckoning, screening, and treatment procedures that may be more fruitful and cause less indication than would be ordinary with standard drugs. By performing more innate tests and examination, authorities may adjust treatment to each patient's needs. Making a tweaked harm screening and treatment game plan consolidates: Determining the chances that a man will make development and choosing screening methods to cut down the threat, Matching patients with meds that will presumably be convincing and cause less responses, Predicting the risk of rehash (return of Cancer).

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 14: Biospecimens as building blocks for Precision Medicine

Biospecimens contain molecules that can be analyzed for indications of diseases. Biospecimens may confirm whether a disease is present or absent in a particular person, and research on biospecimens is especially helpful for understanding more about how disease processes may start and progress. This understanding may lead to better detection of diseases at the earliest stages and may permit design of more effective treatments. Annotated human biospecimens are critical building blocks for precision medicine discovery and essential to the preclinical validation of resulting hypotheses. In this session, learn how advances in technology are improving access to a diverse range of biospecimens from patient populations and yielding increasingly useful amounts of information upon analysis.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 15: Personalized Modeling of Precision Health

Personalized Medicine is a creating routine of remedy that uses a person's inherited profile to direct decisions made as for the balancing activity, investigation, and treatment of ailment. Learning of a patient's innate profile can offer experts some help with choosing the right solution or treatment and control it using the most ideal estimations or regimen. Used for the treatment as Personalized harm pharmaceutical, Diabetes-related disorder: danger assessment and organization, Personalized medication: New strategies and fiscal repercussions, Implications of altered solution in treatment of HIV, Applications of modified remedy in exceptional contaminations, Translational Medicine.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 16: Personalized Health Care Delivery

Personalized drug is a field of prescription that includes anticipating the probability of disease and building up preventive measures remembering the true objective to either keep the infirmity all things considered or out and out reduction its impact upon the patient, (for instance, by maintaining a strategic distance from mortality or compelling grimness). Strategies and measures join New-conceived screening, diagnostic testing, Medical bioinformatics, Prenatal testing, Carrier testing, Preconception testing. Newborn child screening is a general prosperity program expected to screen babies not long after origination for a summary of conditions that are treatable, however not clinically clear in the baby time frame. Pre-birth testing: Prenatal testing is used to look for disorders and conditions in a hatchling or creating life before it is imagined. This sort of testing is offered for couples who have an extended peril of having a youngster with an innate or chromosomal issue. Screening can choose the sex of the incipient organism. Pre-birth testing can offer a couple some help with choosing whether to rashly end the pregnancy. Like symptomatic testing, pre-birth testing can be non-obtrusive or meddlesome. Non-prominent techniques fuse examinations of the woman's womb through ultrasonography or maternal serum screens. These non-nosy methodology can evaluate risk of a condition, however can't choose with conviction if the developing life has a condition.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 17: Treatment of Genetic Disorders

Gene therapy is hoped to cure or improve treatment of genetic disorders by replacing the mutated or malfunctioned gene, manipulating or turning off the gene causing the disease or stimulate other bodily functions to fight the disease. The most common method is replacement of a malfunctioned or sometimes a missed gene with a healthy one. However, gene therapy poses a risk of potentially serious complications, in the first place due to the method that is used to insert the new genes the use of viruses. These have the ability to identify certain cells as well as to transmit the genetic material into the cells containing malfunctioned or missed gene. For that reason modified viruses are used as vectors or carriers of the healthy genes. This method of insertion of healthy genes may not seem problematic at a first glance but it can cause cause potentially serious complications as already mentioned earlier.

♫ Posted in Personalized Medicine | | Comments Off»

Banking Menstrual Stem Cells | What are Menstrual Stem …

♫ Sunday, April 14th, 2019

Stem cells in menstrual blood have similar regenerative capabilities as thestem cells in umbilical cord blood and bone marrow. Cryo-Cell's patent-pendingmenstrual stem cell service offers women in their reproductive years the ability to store and preserve these cells for potential use by herself or a family memberfree from ethical or political controversy.

Cryo-Cell is the only stem cell bank in the world that can offer womenthe reassurance and peace of mind that comes with this opportunity.

What are menstrual stem cells?Stem cells in menstrual blood are highly proliferativeandpossess the unique ability to develop into various other types of healthy cells. During a womans menstrual cycle, these valuable stem cells are discarded.

Cryo-Cell'smenstrual stem cell bankingservice captures those self-renewing stem cells, processes and cryopreserves them for emerging cellular therapies that hold the promise of potentially treatinglife-threatening diseases.

How are menstrual stem cells collected, processed and stored?The menstrual blood is collected in a physicians officeusing a medical-grade silicone cup in place of a tampon orsanitary napkin. The sample is shipped to Cryo-Cell via a medical courier and processed in our state-of-the-art ISO Class 7 clean room.

The menstrual stem cells are stored in two cryovials that are overwrapped to safeguard them during storage. The overwrapped vials are cryogenically preserved in a facility that isclosely monitored at all times to ensure that your menstrual stem cells are safe and ready for future use.

What are the benefits of banking menstrual stem cells?Cryo-Cell's innovative menstrual stem cell banking service provides women with the exclusive opportunity to build their own personal healthcare portfolio with stem cells that will be a 100% match for the donor. Menstrual stem cells have demonstrated the capability of differentiating into many other types of stem cells such as cardiac, neural, bone, fat and cartilage.

Bankingmenstrual stem cells now is an investment in your future medical needs. Currently, they are being studied to treat stroke, heart disease, diabetes, neurodegenerative disease, and ischemic wounds in pre-clinical and clinical models.

Cryo-Cells activities for New York State residents are limited to collection, processing, and long-term storage ofmenstrual stem cells. Cryo-Cells possession of a New York State license for such collection, processing, and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells.

Original post:
Banking Menstrual Stem Cells | What are Menstrual Stem ...

♫ Posted in Fat Stem Cells | | Comments Off»

Nanomedicine | Ardena

♫ Sunday, April 14th, 2019

This fast-evolving field uses nanoscale or nanostructured materials to impart unique pharmacokinetic and therapeutic effects such as enhanced dissolution rate and oral bioavailability, targeted delivery, enhanced efficacy and reduced toxicity.

The control of materials in the nanometer size range requires scientifically demanding chemistry, analysis and manufacturing techniques. Our nanomedicine expertise encompasses formulation, process and analytical development, GMP manufacturing and dossier development.

We are experts in the following formulations:

Once we identify a suitable formulation, our scientists develop phase-appropriate production processes in accordance with cGMP and mitigate technology transfer issues by using the same teams for development and manufacturing.

Techniques include:

In our cGMP-compliant manufacturing facilities, we can produce volumes of a couple of millilitres to multiple litres, using batch-type and continuous-flow processes. We also work with highly-potent drug substances and can deliver nanosuspensions and nanoparticle solutions as sterile finished drug products in vials or syringes.

To support product development and to perform quality control of GMP-produced drug products, we utilise state-of-the-art analytical techniques such as:

Having advanced a wide range of nanomedicine formulations into the clinic, we are used to developing new manufacturing techniques and analytical procedures under fierce regulatory scrutiny. Our understanding of the regulatory landscape gives your nanomedicine project the greatest chance of approval.

Read the original:
Nanomedicine | Ardena

♫ Posted in Nano medicine | | Comments Off»

Regenerative Medicine – Tucson Orthopaedic Institute

♫ Saturday, April 13th, 2019

To treat certain orthopaedic conditions, Tucson Orthopaedic Institute is now providing regenerative medicine procedures, including dextrose prolotherapy, platelet-rich plasma (PRP), and stem cells.Our physicians have experience in both traditional and minimally invasive techniques.

Dextrose prolotherapy is a form of injection therapy designed to stimulate healing. It works by causing temporary, low grade inflammation that increases the level of growth factors at the injection sight and initiates a healing cascade. This healing cascade results in the repair of soft tissue structures, such as ligaments and tendons.Dextrose prolotherapy is a long-term solution to musculoskeletal injuries and pain. It is effective in ligament and tendon pathology and also helps to stabilize arthritic joints. For prolotherapy treatment, please schedule an appointment with Dr. Taduran.

Platelet Rich Plasma (PRP), like dextrose prolotherapy, is a form of injection therapy designed to stimulate healing.Unlike dextrose prolotherapy, PRP is produced after drawing blood from the patient and placing it in a special centrifuge that separates and concentrates the platelets.Platelets contain multiple growth factors that are critical for natural healing.Enhanced healing occurs when platelet concentration is increased with PRP.Our final PRP product produces greater than 4x the platelet concentration of normal circulating blood.The PRP is then injected into ligaments, tendons, muscle, or joints and a healing cascade occurs.PRP is a long-term solution to musculoskeletal injuries and pain, including arthritic joints. For PRP treatment, please schedule an appointment with Dr. DeWald or Dr. Taduran.

The Uniqueness of Stem CellsStem Cells have several unique abilities. They can transform into other cell types, such as bone, cartilage, muscle and tendon. And they also serve an important signaling functioning, recruiting other stem cells to the target area and triggering nearby cells to begin the repair process.

What are Adult Mesenchymal Stem Cells?

Stem Cellsare undifferentiated cells that have the potential to become other, more specialized types of cells. Stem cells are broadly categorized as either embryonic or adult. As the name implies, embryonic stem cells are derived from human fetuses, whereas adult stem cells are obtained from, well, adults!

Currently, there are over 70 proven therapies using adult stem cells, while there are none using embryonic stem cells. This is in part because scientists have had tremendous difficulty controlling how embryonic stem cells differentiate; they have a nasty habit of causing tumor formation, including teratomas. Adult stem cells, on the other hand, do not suffer from this pitfall.

Mesenchymal stem cells, orMSCs, aremultipotentstem cells that can differentiate into a variety of cell types, including:osteoblasts(bone cells),chondrocytes(cartilage cells) andadipocytes(fat cells). This has been demonstrated inex vivocultures andin vitroor in vivo. MSCs are obtained from the bone marrow, most commonly the back of the iliac crest (the hip bone)

How Are MSCs Obtained?

Harvesting MSCs for injection therapy is done right in the office. Stem cells can beobtained from the bone marrow or fat tissue. The skin is numbed first with lidocaine. Next, the hip bone is numbed with more lidocaine. A special needle is then passed through the cortex of the bone into the marrow cavity. This is a painless procedure in most cases. The liquid marrow is then very slowly drawn into a syringe. Once an adequate amount of liquid marrow is obtained, the needle is removed and a bandage applied.

To see a brief animated video of how the procedure is performed, click this here.The entire procedure takes about 20 minutesand it is minimally uncomfortable.

Fat Grafting

In the case of moderate-to-large tendon and muscle tears, such as rotator cuff, tennis elbow, and Achilles, stem cell treatment alone may be less effective because the liquid stem cell solution has less tendency to stay in the tear; it leaks out. In order to combat this, we often will combine stem cells with fat concentrate to create a gel that fills the defect and promotes more effective healing.

Likewise with more advanced joint arthritis, the fat acts a matrix to help hold the platelets in place and also helps activate them to release their growth factors more effectively. Think of a garden trellis that helps hold a growing vine in place. In fact, for moderate-to-advanced arthritis, our standard treatment is to combine the stem cell solution with the fat due to the fact that it seems to work that much better than stem cells alone.

The fat is harvested from the patients belly, buttocks, love handles, or hips using a gentle liposuction technique. The fat is processed while you wait to help liberate the stem cells and other supporting cells in the fat. The resulting gel fills the tear in the case of tendons/muscles and helps maintain more constant contact with the joint surfaces in the case of arthritis. An overview can be seen here.

How Are Stem Cell Injections Given?

All of our stem cell, PRP, and prolotherapy injections are given under direct ultrasound guidance. We first numb the skin with lidocaine. Then, using ultrasound, we guide the needle to the precise location and inject the stem cells. The ultrasound guidance ensures both accurate and safe injections.

Following injection, for weight-bearing joints (ankles/feet, knees, hip) patients need to avoid bearing weight for 24-72 hours. But it is critical that the joint NOT be immobilized. Gentle protected movement is critical to stimulate healing. For non-weight bearing joints, gentle protected movement is generally encouraged, but forceful or aggressive activity, such as sports, is prohibited. Your doctor will give you more specific post-injection activity guidelines.

What Conditions Might Benefit From Stem Cell Injections?

Stem cell injections are most commonly used for the treatment of conditions that have failed or responded incompletely to other more conservative treatments. Conditions include, but are not limited to:

Osteoarthritis of the joints

Chronic partial Rotator Cuff Tears

Persistent partial tendon tears, such as tennis elbow, plantar fasciitis, quadriceps and patellar tendon tears.

Partial muscle tears

Meniscal and labral (cartilage) tears in the knee, hip and shoulder

Chondromalacia patella (patellofemoral syndrome)

Are There Risks Associated With Stem Cell Treatment?

Any injection is potentially at-risk for causing infection, bleeding, nerve damage. Risks will also vary depending on the structure(s) being injected. However, because we are using your own cells, you cannot be allergic to the treatment! Also, because the injections are done under ultrasound guidance, the risks of damaging surrounding structures, or of injecting the wrong location, are almost completely eliminated. Your doctor will review the complete risks of treatment with you. Nonetheless, the risks of treatment are extremely low.

Are Stem Cell Treatments Covered by Insurance?

Currently stem cell injections are still considered experimental. Most insurance plans, including Medicare, do NOT pay for stem cell injections.

When Can I Expect to See Improvement?

On average, most patients start to see signs of improvement approximately 6-8 weeks after the completion of the complete treatment protocol. This can be less overall pain, an ability to do more activity before pain sets in, and/or faster recovery from pain.

What is the Success Rate?

Studies suggest an improvement rate as high as 80-90%, though some arthritic joints, namely the hip, do not respond as well. Some patients experience complete relief of their pain. In the case of tendon and ligament injuries the results are generally permanent. In the case of joint arthritis, how long the treatment lasts depends partly on the severity of the condition. Mild arthritis may not need another round of treatments. More advanced arthritis, on the other hand, may require a repeat course of treatment, usually in 1-3 years.

The anecdotal experience in our office closely mirrors that of published studies. Regarding arthritis, our experience is that knees and shoulders respond the best, with 80-90% of patients experiencing improvement. 70% of patients with hip arthritis have a positive response.

Excerpt from:
Regenerative Medicine - Tucson Orthopaedic Institute

♫ Posted in Regenerative Medicine | | Comments Off»

Regenerative Medicine | NorthShore

♫ Saturday, April 13th, 2019

Regenerative medicine includes minimally and non-invasive techniques that help the body heal damaged or traumatized tissue using stem cells as an alternative to a joint replacement or surgical procedure. Stem cells, which are immature cells, are taken from a patients body (typically from the bone marrow) or donated, and injected into the site of the injury. The cells recognize the damage and mature into the necessary cell to repair the area. The process, called a bone marrow concentrate procedure, can be used to help heal many parts of the body. In addition, stem cells can also be utilized to create scaffolds made of tissue, which also enhance the bodys ability to heal.

At NorthShore, our orthopaedic team includes physicians who have specialized in regenerative medicine for the treatment of common and often chronic orthopaedic conditions such as arthritis, plantar fasciitis, tendinopathy, rotator cuff injuries, chronic tennis elbow and various forms of muscular strains and tears. Patients who do not respond to traditional treatments or are not good candidates for surgery may qualify for regenerative medicine therapies.

Additionally, our team is performing research studies and clinical trials to further identify the capabilities of regenerative medicine. Current studies are looking at cells to enhance the healing of knee cartilage using platelet-rich plasma for patients with knee arthritis. Other studies will be focused on how regenerative medicine can be utilized to improve recovery for professional athletes.

For More Information

If you are interested in learning more about regenerative medicine or to request a consultation, please call855.929.0100orfill out the consultation request form.

Link:
Regenerative Medicine | NorthShore

♫ Posted in Regenerative Medicine | | Comments Off»

Stem Cell Basics VII. | stemcells.nih.gov

♫ Thursday, April 11th, 2019

There are many ways in which human stem cells can be used in research and the clinic. Studies of human embryonic stem cells will yield information about the complex events that occur during human development. A primary goal of this work is to identify how undifferentiated stem cells become the differentiated cells that form the tissues and organs. Scientists know that turning genes on and off is central to this process. Some of the most serious medical conditions, such as cancer and birth defects, are due to abnormal cell division and differentiation. A more complete understanding of the genetic and molecular controls of these processes may yield information about how such diseases arise and suggest new strategies for therapy. Predictably controlling cell proliferation and differentiation requires additional basic research on the molecular and genetic signals that regulate cell division and specialization. While recent developments with iPS cells suggest some of the specific factors that may be involved, techniques must be devised to introduce these factors safely into the cells and control the processes that are induced by these factors.

Human stem cells are currently being used to test new drugs. New medications are tested for safety on differentiated cells generated from human pluripotent cell lines. Other kinds of cell lines have a long history of being used in this way. Cancer cell lines, for example, are used to screen potential anti-tumor drugs. The availability of pluripotent stem cells would allow drug testing in a wider range of cell types. However, to screen drugs effectively, the conditions must be identical when comparing different drugs. Therefore, scientists must be able to precisely control the differentiation of stem cells into the specific cell type on which drugs will be tested. For some cell types and tissues, current knowledge of the signals controlling differentiation falls short of being able to mimic these conditions precisely to generate pure populations of differentiated cells for each drug being tested.

Perhaps the most important potential application of human stem cells is the generation of cells and tissues that could be used for cell-based therapies. Today, donated organs and tissues are often used to replace ailing or destroyed tissue, but the need for transplantable tissues and organs far outweighs the available supply. Stem cells, directed to differentiate into specific cell types, offer the possibility of a renewable source of replacement cells and tissues to treat diseases including maculardegeneration, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

Figure 3. Strategies to repair heart muscle with adult stem cells. Click here for larger image.

2008 Terese Winslow

For example, it may become possible to generate healthy heart muscle cells in the laboratory and then transplant those cells into patients with chronic heart disease. Preliminary research in mice and other animals indicates that bone marrow stromal cells, transplanted into a damaged heart, can have beneficial effects. Whether these cells can generate heart muscle cells or stimulate the growth of new blood vessels that repopulate the heart tissue, or help via some other mechanism is actively under investigation. For example, injected cells may accomplish repair by secreting growth factors, rather than actually incorporating into the heart. Promising results from animal studies have served as the basis for a small number of exploratory studies in humans (for discussion, see call-out box, "Can Stem Cells Mend a Broken Heart?"). Other recent studies in cell culture systems indicate that it may be possible to direct the differentiation of embryonic stem cells or adult bone marrow cells into heart muscle cells (Figure 3).

Cardiovascular disease (CVD), which includes hypertension, coronary heart disease, stroke, and congestive heart failure, has ranked as the number one cause of death in the United States every year since 1900 except 1918, when the nation struggled with an influenza epidemic. Nearly 2,600 Americans die of CVD each day, roughly one person every 34 seconds. Given the aging of the population and the relatively dramatic recent increases in the prevalence of cardiovascular risk factors such as obesity and type 2 diabetes, CVD will be a significant health concern well into the 21st century.

Cardiovascular disease can deprive heart tissue of oxygen, thereby killing cardiac muscle cells (cardiomyocytes). This loss triggers a cascade of detrimental events, including formation of scar tissue, an overload of blood flow and pressure capacity, the overstretching of viable cardiac cells attempting to sustain cardiac output, leading to heart failure, and eventual death. Restoring damaged heart muscle tissue, through repair or regeneration, is therefore a potentially new strategy to treat heart failure.

The use of embryonic and adult-derived stem cells for cardiac repair is an active area of research. A number of stem cell types, including embryonic stem (ES) cells, cardiac stem cells that naturally reside within the heart, myoblasts (muscle stem cells), adult bone marrow-derived cells including mesenchymal cells (bone marrow-derived cells that give rise to tissues such as muscle, bone, tendons, ligaments, and adipose tissue), endothelial progenitor cells (cells that give rise to the endothelium, the interior lining of blood vessels), and umbilical cord blood cells, have been investigated as possible sources for regenerating damaged heart tissue. All have been explored in mouse or rat models, and some have been tested in larger animal models, such as pigs.

A few small studies have also been carried out in humans, usually in patients who are undergoing open-heart surgery. Several of these have demonstrated that stem cells that are injected into the circulation or directly into the injured heart tissue appear to improve cardiac function and/or induce the formation of new capillaries. The mechanism for this repair remains controversial, and the stem cells likely regenerate heart tissue through several pathways. However, the stem cell populations that have been tested in these experiments vary widely, as do the conditions of their purification and application. Although much more research is needed to assess the safety and improve the efficacy of this approach, these preliminary clinical experiments show how stem cells may one day be used to repair damaged heart tissue, thereby reducing the burden of cardiovascular disease.

In people who suffer from type1 diabetes, the cells of the pancreas that normally produce insulin are destroyed by the patient's own immune system. New studies indicate that it may be possible to direct the differentiation of human embryonic stem cells in cell culture to form insulin-producing cells that eventually could be used in transplantation therapy for persons with diabetes.

To realize the promise of novel cell-based therapies for such pervasive and debilitating diseases, scientists must be able to manipulate stem cells so that they possess the necessary characteristics for successful differentiation, transplantation, and engraftment. The following is a list of steps in successful cell-based treatments that scientists will have to learn to control to bring such treatments to the clinic. To be useful for transplant purposes, stem cells must be reproducibly made to:

Also, to avoid the problem of immune rejection, scientists are experimenting with different research strategies to generate tissues that will not be rejected.

To summarize, stem cells offer exciting promise for future therapies, but significant technical hurdles remain that will only be overcome through years of intensive research.

Previous|VII. What are the potential uses of human stem cells and the obstacles that must be overcome before these potential uses will be realized?|Next

Read the original:
Stem Cell Basics VII. | stemcells.nih.gov

♫ Posted in Death by Stem Cells | | Comments Off»

Cancers Trick for Dodging the Immune System

♫ Wednesday, April 10th, 2019

Cancer immunotherapy drugs, which spur the bodys own immune system to attack tumors, hold great promise but still fail many patients. New research may help explain why some cancers elude the new class of therapies, and offer some clues to a solution.

The study, published on Thursday in the journal Cell, focuses on colorectal and prostate cancer. These are among the cancers that seem largely impervious to a key mechanism of immunotherapy drugs.

The drugs block a signal that tumors send to stymie the immune system. That signal gets sent via a particular molecule that is found on the surface of some tumor cells.

The trouble is that the molecule, called PD-L1, does not appear on the surface of all tumors, and in those cases, the drugs have trouble interfering with the signal sent by the cancer.

[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]

The new study is part of a growing body of research that suggests that even when tumors dont have this PD-L1 molecule on their surfaces, they are still using the molecule to trick the immune system.

Instead of appearing on the surface, the molecule is released by the tumor into the body, where it travels to immune system hubs, the lymph nodes, and tricks the cells that congregate there.

They inhibit the activation of immune cells remotely, said Dr. Robert Blelloch, associate chairman of the department of urology at the University of California, San Francisco, and a senior author of the new paper.

The U.C.S.F. scientists discovered that they could cure a mouse of prostate cancer if they removed the PD-L1 that was leaving the tumor and traveling to the lymph nodes to trick the immune system. When that happened, the immune system attacked the cancer effectively.

Furthermore, the immune system of the same mouse seemed able to attack a tumor later even when the drifting PD-L1 was reintroduced. This suggested to Dr. Blelloch that it might be possible to train the immune system to recognize a tumor much the way a vaccine can train an immune system to recognize a virus.

The work was done not in humans but in laboratory experiments and in mice, and it is not clear whether the results will translate in people. Dr. Ira Mellman, vice president of cancer immunology at Genentech, called the findings a most interesting result.

But as with all mouse experiments, you get insight into basic mechanisms, but how it translates to the human therapeutic setting is unclear, said Dr. Mellman. He is skeptical, he said, but plans to meet shortly with Dr. Blelloch to discuss the implications of the work.

The new research dovetails with other recent studies, including a paper published last year in the journal Nature that showed that PD-L1 molecules released from skin cancer tumors can suppress the bodys immune function.

When these bits of PD-L1 travel outside the cell, they are known as exosomal, and the discovery of their role is one of many fast-moving developments refining an area of medicine that has become among the most promising in decades.

Late last year, the Nobel Prize was awarded to two scientists James P. Allison of the M.D. Anderson Cancer Center in Houston, and Tasuku Honjo of Kyoto University in Japan who did groundbreaking work in immunotherapy.

An explosion of additional research is aimed not only at refining the therapies which can have profound side effects but also at searching for other molecules involved in the perilous dance between cancer and the immune system.

Far more study is needed. But Dr. Blelloch said the findings have him looking for ways to take the next steps into turning the discovery into a concrete therapy.

Interfering with the PD-L1 traveling to lymph nodes can lead to a long-lasting, systemic, anti-tumor immunity, the paper concluded.

Go here to see the original:
Cancers Trick for Dodging the Immune System

♫ Posted in Immune System | | Comments Off»

Integrative medicine: Alternative becomes mainstream – Mayo …

♫ Wednesday, April 10th, 2019

Integrative medicine: Alternative becomes mainstream

What's considered an alternative therapy is a moving target. Learn the lingo and get the facts.

Complementary medicine has never been more popular. Nearly 30 percent of adults report using complementary and alternative medicine (CAM). Doctors are embracing CAM therapies, too, often combining them with mainstream medical therapies spawning the term "integrative medicine."

Exactly what's considered complementary medicine changes constantly as treatments undergo testing and move into the mainstream. To make sense of the many therapies available, it helps to look at how they're classified by the National Center for Complementary and Integrative Health (NCCIH):

Examples include dietary supplements and herbal remedies. These treatments use ingredients found in nature. Examples of herbs include ginseng, ginkgo and echinacea; examples of dietary supplements include selenium, glucosamine sulfate and SAMe. Herbs and supplements can be taken as teas, oils, syrups, powders, tablets or capsules.

Mind-body techniques strengthen the communication between your mind and your body. CAM practitioners say these two systems must be in harmony for you to stay healthy. Examples of mind-body connection techniques include meditation, prayer, relaxation and art therapies.

Manipulation and body-based practices use human touch to move or manipulate a specific part of your body. They include chiropractic and osteopathic manipulation and massage.

Some CAM practitioners believe an invisible energy force flows through your body, and when this energy flow is blocked or unbalanced, you can become sick. Different traditions call this energy by different names, such as chi, prana and life force. The goal of these therapies is to unblock or re-balance your energy force. Energy therapies include qi gong, healing touch and reiki.

There are other approaches to complementary health that focus on a system, rather than just a single practice or remedy, such as massage. These systems center on a philosophy, such as the power of nature or the presence of energy in your body. Examples of these approaches include:

Many conventional doctors practicing today didn't receive training in CAM or integrative medicine, so they may not feel comfortable making recommendations or addressing questions in this area.

Doctors also have good reason to be cautious when it comes to some CAM. Conventional medicine values therapies that have been demonstrated through research and testing to be safe and effective. While scientific evidence exists for some CAM therapies, for many there are key questions that are yet to be answered.

In addition, some CAM practitioners make exaggerated claims about curing diseases, and some ask you to forgo treatment from your conventional doctor. For these reasons, many doctors are cautious about recommending these therapies.

One reason for the lack of research in alternative treatments is that large, carefully controlled medical studies are costly. Trials for conventional therapies are often funded by big companies that develop and sell drugs. Fewer resources are available to support trials of CAM therapies. That's why NCCIH was established to foster research into CAM and make the findings available to the public.

Work with your conventional medical doctor to help you make informed decisions regarding CAM treatments. Even if your doctor can't recommend a specific practitioner, he or she can help you understand possible risks and benefits before you try a treatment.

It's especially important to involve your doctor if you are pregnant, have medical problems or take prescription medicine. And don't stop or change your conventional treatment such as the dose of your prescription medications without talking to your doctor first. Finally, be sure to keep your doctor updated on any alternative therapies you're using, including herbal and dietary supplements.

.

Read this article:
Integrative medicine: Alternative becomes mainstream - Mayo ...

♫ Posted in Integrative Medicine | | Comments Off»

Benefits of Human Genetic Engineering

♫ Wednesday, April 10th, 2019

QUESTION: What are the benefits of human genetic engineering?

ANSWER:

The benefits of human genetic engineering can be found in the headlines nearly every day. With the successful cloning of mammals and the completion of the Human Genome Project, scientists all over the world are aggressively researching the many different facets of human genetic engineering. These continuing breakthroughs have allowed science to more deeply understand DNA and its role in medicine, pharmacology, reproductive technology, and countless other fields.

The most promising benefit of human genetic engineering is gene therapy. Gene therapy is the medical treatment of a disease by repairing or replacing defective genes or introducing therapeutic genes to fight the disease. Over the past ten years, certain autoimmune diseases and heart disease have been treated with gene therapy. Many diseases, such as Huntington's disease, ALS (Lou Gehrig's disease), and cystic fibrosis are caused by a defective gene. The hope is that soon, through genetic engineering, a cure can be found for these diseases by either inserting a corrected gene, modifying the defective gene, or even performing genetic surgery. Eventually the hope is to completely eliminate certain genetic diseases as well as treat non-genetic diseases with an appropriate gene therapy.

Currently, many pregnant women elect to have their fetuses screened for genetic defects. The results of these screenings can allow the parents and their physician to prepare for the arrival of a child who may have special needs before, during, and after delivery. One possible future benefit of human genetic engineering is that, with gene therapy, a fetus w/ a genetic defect could be treated and even cured before it is born. There is also current research into gene therapy for embryos before they are implanted into the mother through in-vitro fertilization.

Another benefit of genetic engineering is the creation pharmaceutical products that are superior to their predecessors. These new pharmaceuticals are created through cloning certain genes. Currently on the market are bio-engineered insulin (which was previously obtained from sheep or cows) and human growth hormone (which in the past was obtained from cadavers) as well as bio-engineered hormones and blood clotting factors. The hope in the future is to be able to create plants or fruits that contain a certain drug by manipulating their genes in the laboratory.

The field of human genetic engineering is growing and changing at a tremendous pace. With these changes come several benefits and risks. These benefits and risks must be weighed in light of their moral, spiritual, legal, and ethical perspectives. The potential power of human genetic engineering comes with great responsibility.

What is your response?

Yes, today I am deciding to follow Jesus

Yes, I am already a follower of Jesus

I still have questions

Read the original:
Benefits of Human Genetic Engineering

♫ Posted in Legal Issues Genetic Medicine | | Comments Off»

Living to 100? Longevity and Genetics Genetic Lifehacks

♫ Monday, April 8th, 2019

There are several genes known as longevity genes that increase your odds of becoming a centenarian. Specific variants of these genes are associated with an increased likelihood of living to be 100 or more. And more importantly, these genetic variants are linked to longer healthspan.

What are the odds of living to 100?Someoneborn a hundred years ago has less than 1% chance of being alive today. If you are female and born in 1973, your odds of living to 100 are 20%. Wondering about the odds for your birth year? Here is a nice chart of your odds of living to 100 based on your birth year:http://discovertheodds.com/what-are-the-odds-of-living-to-100/

So if your odds of living to 100 are 20%, a gene that increases that by 1.5x or 2xis actually significant.Keep in mind, though, that while genetics does play a role in how long you live, there are other health and lifestyle factors that are also important. This is all about statistics here.

FOXO3A gene:

The FOXO3A gene (forkhead box O3) has been linked to longevity in several different studies. This gene is believed to regulate apoptosis, which is necessary for cell death, and is a tumor suppressor. One study describes it thus FOXO proteins have been involved in the regulation of response to oxidative stress, starvation and caloric restriction with the final effect of increasing lifespan and prevent aging-related diseases, such as diabetes and cancer[ref]For the SNP rs2802292, the G allele was found to be an indicator of longevity. The odds ratio of living longer for G/G vs. T/T was found to be 2.75 in a study of Japanese males. Another study of Italians found that a proxy of the SNP above is associated with a 1.5x increase in odds of longevity.

CETP Gene:Another gene related to longevity is the CETP gene (cholesteryl ester transfer protein) which is involved in exchanging triglycerides with cholesteryl esters. One polymorphism that is related to longevity is rs5882 (also referred to as I405V). The G allele is associated with a somewhat longer lifespan. Heterozygotes (A/G) and homozygotes (G/G) are more likely to have a longer lifespan and have higher HDL cholesterol. Homozygotes (G/G) also have a .28x lower risk of dementia and a .31x lower risk of Alzheimers! [study]

Check your 23andMe results for rs5882 (V.4, v.5):

IGF1R gene:The IGF1R gene codes for the insulin-like growth factor 1 receptor. IGF1 is a hormone that signals for growth and anabolic activities. Growth hormone levels generally fall as we age.

Carrying the genes that increase my chance of living to 100 has changed my attitude and way of thinking about getting older. First, planning for retirement is important! But even more on my mind is that the things that I do now to optimize my health will pay off in the long run with a longer healthspan. Prevention of Alzheimers Disease and optimizing my Circadian Rhythmare top on my list of lifehacks this year.

The OkinawanDiet is thought to promote healthy longevity in part through affecting FOXO3. The diet focuses on fresh vegetables, fish, lean meats, omega-3 fats, and unrefined carbohydrates.

Green tea polyphenols (EGC/G) have been found to increase FOXO3 levels.

Astaxanthin, naturally found in shrimp, salmon, and red algae, has been found to increase FOXO3 levels.[ref] If you arent getting enough astaxanthin from your diet, you can get it as a supplement.

♫ Posted in Longevity Genetics | | Comments Off»

Biotechnology Careers – Career Path Information | Monster.com

♫ Sunday, April 7th, 2019

Biotechnology Career Overview

If biology is your bag, you may be interested in biotech careers. Biological technicians often work at universities or in commercial labs assisting with experiments and tests. Biochemists, biophysicists and microbiologists are biotech jobs worked in universities or commercial or private offices and labs studying organisms, microorganisms, biological development and growth.

If you're looking at biotechnology careers, be prepared to get an education. Technicians and microbiologists need at least a bachelor's degree in biology, microbiology or a related field. Biochemists and biophysicists need a doctoral degree to find employment doing independent research and even development. Occasionally, you may find an entry-level biotech job that only requires a bachelor's or master's degree, but you'll want to go on to complete your Ph.D. if you aspire to move up the biotechnology ladder.

Overall, biotech careers are expected to increase in demand over the next 10 years. The Bureau of Labor Statistics (BLS) projects a 10 percent growth for biological techs, biochemists and biophysicists between 2012 and 2022, and a seven percent increase in microbiologists' jobs. Increased demand for research in the biotechnology field and the aging baby boomer population are the key issues that the BLS names for the positive job market outlook in these fields. That's good news for biochemists, biophysicists and microbiologists, as they held roughly only 49,300 jobs in 2012. The biotech techs, however, were almost double the other three biotech careers combined, expected to be around 88,300 by 2022, up from 80,200 jobs in 2012.

As with any job that requires a degree, biotech positions command higher salaries. Techs are the low men on the totem pole with an average annual salary of $38,750. If you put the time and effort into earning a master's degree or a Ph.D. for one of the other biotech jobs, however, the pay increases. Microbiologists earn an annual median wage of $66,260 and biochemists and biophysicists bring in even more with average annual pay at $81,480.

Minimize Infographic

Share Options:

Share On Your Site:

Created by Monster.com. Find Better.

Continue reading here:
Biotechnology Careers - Career Path Information | Monster.com

♫ Posted in Biotechnology | | Comments Off»

Bone Marrow Stem Cells | NSI Stem Cell

♫ Sunday, April 7th, 2019

Stem cell therapies have come a long way since the 1970s and 1980s. Today the ethical issues of harvesting stem cells have long been resolved through the discovery of several sources of potent stem cell types. Common sources include in the umbilical cord and placenta (post birth), bone marrow, and the fatty layer that lies just beneath everyones skin (adipose fat tissue). Of these resources, by far the most commonly accessed in the United States are adipose fat and bone marrow stem cells.The National Stem Cell Institute (NSI), a leading stem cell clinic in the U.S., has seen the development of these living resources usher in an exciting new age known as regenerative medicine. Because of their potency and new technologies that allow ease of access, stem cells are changing the very face of medicine. In particular, the harvesting of bone marrow stem cells has developed into a procedure that is minimally invasive, far more comfortable than bone marrow harvesting of the past, and able to be complete in just a few hours.Some Basics About Bone Marrow Stem CellsBone marrow is the living tissue found in the center of our bones. Marrow is a soft, sponge-like tissue. There are two types of bone marrow: red marrow and yellow marrow. In adults, red marrow is found mainly in the central skeleton, such as the pelvis, sternum, cranium, ribs, vertebrae, and scapulae. But it is also found in the ends of long bones such as in the arms and legs.When it comes to bone marrow stem cells, red marrow is what its all about. Red marrow holds an abundance of them. Stem cells are a kind of protocell that has not yet been assigned an exact physical or neurological function. You can think of them as microscopic packets of potential that stay on high alert for signals telling them where they are needed and what type of cell they need to become.Bone marrow stem cells are multipotent, which means they have the ability to become virtually any type of tissue cell, including:

Continued here:
Bone Marrow Stem Cells | NSI Stem Cell

♫ Posted in Fat Stem Cells | | Comments Off»

Morristown Ophthalmology – Cataract Surgery NJ

♫ Sunday, April 7th, 2019

Dr. Reisman is one of only a few ophthalmologists in Morristown, NJ who is fellowship trained in cornea and refractive laser eye surgery. Having performed more than 15,000 laser eye surgery procedures at his Morris County practice, New Jersey surgeon Dr. Reisman has the experience patients seek, and offers personalized care and a unique treatment plan for each individual.

Are you searching for a cataract surgeon in the Morristown, New Jersey area? Now you can see better after laser cataract surgery with new premium lens implants. Trust the talent of Dr. Reisman to ensure the best results and patient care, offering advances such as laser cataract surgery and premium lens options.

At Morristown Ophthalmology Associates, "Our focus is on your eyes." Our commitment to patient satisfaction is a priority. Dr. Reisman encourages his patients to set up a free consultation and explore laser vision correction options at his Morristown, Morris County office.

Morristown Ophthalmology Associates offers patient financing with Wells Fargo. Please contact our office to learn more about your available options.

Continue reading here:
Morristown Ophthalmology - Cataract Surgery NJ

♫ Posted in Opthalmology | | Comments Off»

#ACTRIMS2019 Stem Cell Tourism Poses Threat of …

♫ Sunday, April 7th, 2019

Academic neurologists are seeing many patients with neurological diseases interested in or receiving unapproved stem cell-based treatments, sometimes with negative health and/or financial consequences, according to a U.S. survey of neurologists.

The data were reported byWijdan Rai, MD, from Ohio State University in aposter titled Complications of Stem Cell Tourism in Multiple Sclerosis & Other Neurological Diseases: Results from First Nationwide Survey of Academic Neurologists on March 1 atthe 4thAnnual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forumin Dallas, Texas.

Stem cell tourism is a blanket term used to describe clinics (in the U.S. or abroad) that offer unproven cell-based interventions to patients with debilitating diseases, such as Parkinsons disease and amyotrophic lateral sclerosis. The phenomenon of stem cell tourism is rising among patients with neurological diseases, including multiple sclerosis (MS).

According to Rai, an alarming number of stem cell clinics have been accessible to patients, and the need for education has been identified.

Academic neurologists often see patients withcomplications due to stem cell tourism. But, the experiences and challenges that neurologists face in the outpatient practices is unknown, Rai said.

Understanding the experiences of neurologists with patients of stem cell tourism is critical to develop a strategy to educatepatients about it. In fact, a fair amount of neurologists had said that they would find really helpful to have some sort of educational tool, because they were not prepared to answer certain questions about stem cell tourism and its complications, said Rai.

To fill this knowledge gap, researchers fromThe Ohio State Universitydeveloped a 25-question survey focused on academic neurologists in the U.S. and their experiences with and attitudes about stem cell tourism, and associated patient-reported complications. The survey wasdistributed using a web toolcalled Synapse to members of the American Academy of Neurology.

Academic neurologists were targeted because they have specialized and informed knowledge about experimental cell-based therapies. In total, 204 across the U.S. completed the survey, andwere specialized in a range of neurological fields, with about one-third of them specializing in MS.

The survey results showed that nine out of 10 neurologists (91%) had been asked about stem cell treatments by patients or family members/caregivers 37% of these patients had an MS diagnosis.

About two out of three respondents (65%) had a patient who had received stem cell therapies.

Patients most often wanted general information about stem cell therapies from their neurologists. Half of the patients requested permission to undergo a stem cell procedure, and 31% approached their neurologist after the procedure.

Among patients undergoing stem cell treatment,33% reported the treatment was performed in the U.S., 22% reported going abroad, and37% reported procedures both in the U.S. and abroad. The procedures abroad were performed inChina, Germany, the Bahamas, Mexico, Russia, and Costa Rica.

Rai said 75% of the physicians indicated that no patient experienced complications from these unapproved stem-cell-based treatments.

However, one in four (25%) reported seeing patients who experienced complications, such as infections, MS deterioration and relapse, stroke, meningoencephalitis, sepsis, tumors, hepatitis C, seizures, or spinal cord injury.

At least three neurologists had patients who died from unapproved stem cell procedures.

These results are sad, Rai toldMS News Today, because there is actually legit, approved research happening on stem cell therapy, and their complication rate is very low. So its tough to see that it can be done really well, but when its done in a sort of unregulated or unapproved sort of fashion, you can not only have a lot of these kind of complications, but also have a huge financial burden.

According to the researcher,patients reported significant financial burden with no benefit, with treatments costing $20,000 to $25,000, up to $80,000 per procedure.

Stem cell tourism is an emerging public health threat, and the resultsdemonstrate an alarming number of unreported complications and negative impact to MS patients, Rai said.

Therefore, the team believes in a multipronged approach to improve the education of MS patients to prevent exploitation and engaging multiple stakeholders in the field, including MS academic societies, licensing boards,and legislative bodies.

Specifically, the researchers suggested the creation of evidence-based education for neurologists and patients, including resources that neurologists can use when discussing stem cell interventions with patients, and videos on proper counseling during these visits, Rai noted.

The team also advocated for the creation of a publicly available national registry where stem cell tourism complications must be reported, and the development of guidelines on how to care for patients who have undergone experimental stem cell procedures with tumor formation, Rai said.

The researcher said that as a physician, you have to respect patients autonomy, and at the end of the day it is their decision, but we also have to keep in mind that we (physicians) have to do what is best for them and communicate that to (our) patients.

Originally posted here:
#ACTRIMS2019 Stem Cell Tourism Poses Threat of ...

♫ Posted in Stem Cell Tourism | | Comments Off»

The UK Cystic Fibrosis Gene Therapy Consortium

♫ Friday, April 5th, 2019

The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

As many of you will know, the UK CF Gene Therapy Consortium (GTC) has brought together teams at Imperial College London and the Universities of Oxford and Edinburgh to vigorously pursue a single goal for the last 17 years, namely to establish whether gene therapy can become a clinically viable option for patients with CF. This form of treatment needs new copies of the CF gene to be introduced into the cells lining the lung, which is hard to achieve because these cells have evolved to keep external molecules out. The CF gene has to be carried past these defences, achievable either by surrounding it with fat (liposomes) or by inserting the CF gene inside a viral vector. Because of these defences, the GTC anticipated that successful gene therapy would require us to investigate several products, with incremental increases in knowledge helping us to overcome these barriers. We introduced the terms Wave 1 (the best liposome available at that time), and Wave 2 (the best viral vector we believe is currently available).

Supported by the CF community, and thereby predominantly funded by the Cystic Fibrosis Trust, we developed the Wave 1 product (the CF gene delivered via a liposome). Subsequently, funded by the National Institute for Health Researchs Efficacy and Mechanism Evaluation (EME) programme, we were able for the first time to demonstrate a significant benefit in lung function compared with placebo in the worlds largest CF gene therapy trial. Since the trial ended, we have spent considerable time presenting the product to the pharmaceutical industry, as it is these companies who have the resources to carry it through to the next step. The consistent response was that whilst they are impressed with the data, they wish to see a higher level of efficacy (which was slightly less than that produced by Orkambi). This boost could be produced by increasing the dose, increasing the dosing frequency, or trying a different type of liposome. We are exploring these possibilities and if this can be achieved, we will reopen these negotiations with a view to supporting a further clinical trial.

In parallel, we have been working for over a decade with a Japanese biotechnology company (DNAVEC, now called ID Pharma), building on knowledge from the Wave 1 programme, and have developed an alternative viral vector to deliver the CF gene (Wave 2 product). Support from the MRC DPFS programme and the Cystic Fibrosis Trust has brought this product to a stage where it can now undergo toxicology testing and larger-scale manufacturing; we have also recently received funding from the Health Innovation Challenge Fund, a collaboration between the Wellcome Trust and the Department of Health and Social Care, to undertake the next steps. We would also like to take this opportunity to warmly thank all of our supporters over many years, including Just Gene Therapy and Flutterby FUNdraisers.

It is now with great pleasure and excitement that we can add the next piece of the puzzle. The GTC is joining forces with two world class organisations in a major collaboration. We will work in partnership with Boehringer Ingelheim, who are an internationally renowned big pharma company with substantial expertise in bringing products through to patients, including in the respiratory field, and also with Oxford BioMedica who are the acknowledged leaders in the field of manufacturing the type of virus we have established as our Wave 2 product. The three partners are coming together to translate the Wave 2 product into clinical trials, and if successful, into routine clinical practice.

The GTC believes that this partnership provides CF patients with the optimal chance to establish gene therapy as routine clinical practice, relevant to all patients irrespective of their mutation status, and in due course to both prevent lung disease as well as treat established problems. Importantly, we can of course offer no guarantee of success, building this programme will not happen overnight and the therapy will only be focused on the problems occurring in the lungs.

We believe this new partnership of three world leading organisations has the greatest chance of realising a parallel new therapeutic pathway for CF patients, and better still, one that will add to the improvements already being seen with small molecule treatments. The gene therapy may have additional benefits: currently we envisage the effect of a single dose lasting for many months or even longer and it is unlikely that gene therapy will suffer from drug-drug interactions. We will regularly update on progress on this website as this exciting programme now unfolds.

7 months ago

The UKCFGTC is pleased to announce that we have received 2.7M to undertake a Phase l/lla nose trial in CF patients using our Wave 2 product, delivering the CFTR gene using a novel lentivirus. This latest support, which builds on many years of gene therapy funding from the Cystic Fibrosis Trust, the National Institute for Health Research(NIHR) and the Medical Research Council(MRC), has been awarded by the Wellcome Trust/Department of Healths Health Innovation Challenge Fund (HICF).

At the same time the Cystic Fibrosis Trusthave awarded an additional 0.5M to continue to support the scientific work underpinning this latest trial over the next two years.

We aim to recruit 24 patients into the Phase l/lla nose trial which will last around 9 months. The study will assess safety, and any changes in molecular endpoints, to provide evidence for the efficacy of the lentivirus. The start point of the trial will depend on the time required for manufacture of the Wave 2 product for clinical delivery; we will further update on timelines once these manufacturing data are available.

We are now focusing our research and development efforts on Wave 2, which has proved to be considerably more efficient than the Wave 1 product (delivering the CFTR gene via liposomes). However, the latter, which led to a stabilisation of lung function significantly different to the decline seen in a placebo group, continues to be discussed with potential commercial partners. We will update further on the outcome of these discussions as soon as possible.

1 year ago

The Consortium are pleased to announce the publication of the results from our multi dose gene therapy clinical trial inLancet Respiratory Medicine.

One hundred and thirty six patients aged 12 and above were randomly assigned to either 5ml of nebulised pGM169/GL67A (gene therapy) or saline (placebo) at monthly intervals over 1 year. Lung function was evaluated using a common clinical measure FEV1.

The clinical trial reached its primary endpoint with patients who received therapy having a significant, if modest benefit in lung function compared with those receiving a placebo. After a year of treatment, in the 62 patients who received the gene therapy, FEV1 was 3.7% greater compared to placebo.

The trial is the first ever to show that repeated doses of a gene therapy can have a meaningful effect on the disease and change the lung function of patients.

More details here.

3 years ago

See original here:
The UK Cystic Fibrosis Gene Therapy Consortium

♫ Posted in Gene therapy | | Comments Off»

Nano Medicine: Meaning, Advantages and Disadvantages

♫ Friday, April 5th, 2019

In this article we will discuss about Nano Medicine:- 1. Meaning of Nano Medicine 2. Advantages of Nano Medicine 3. Disadvantages.

The application of nanotechnology in medicine is often referred to as Nano medicine. Nano medicine is the preservation and improvement of human health using molecular tools and molecular knowledge of the human body. It covers areas such as nanoparticle drug delivery and possible future applications of molecular nanotechnology (MNT) and Nano-vaccinology.

The human body is comprised of molecules. Hence, the availability of molecular nanotechnology will permit dramatic progress in human medical services. More than just an extension of molecular medicine, Nano medicine will help us understand how the biological machinery inside living cells operates at the Nano scale so that it can be employed in molecular machine systems to address complicated medical conditions such as cancer, AIDS, ageing and thereby bring about significant improvement and extension of natural human biological structure and function at the molecular scale.

Nano medical approaches to drug delivery centre on developing Nano scale particles or molecules to improve drug bioavailability that refers to the presence of drug molecules in the body part where they are actually needed and will probably do the most good. It is all about targeting the molecules and delivering drugs with cell precision.

The use of Nano robots in medicine would totally change the world of medicine once it is realized. For instance, by introducing these Nano robots into the body damages and infections can be detected and repaired. In short it holds that capability to change the traditional approach of treating diseases and naturally occurring conditions in the human beings.

1. Advanced therapies with reduced degree of invasiveness.

2. Reduced negative effects of drugs and surgical procedures.

3. Faster, smaller and highly sensitive diagnostic tools.

4. Cost effectiveness of medicines and disease management procedures as a whole.

5. Unsolved medical problems such as cancer, benefiting from the Nano medical approach.

6. Reduced mortality and morbidity rates and increased longevity in return.

1. Lack of proper knowledge about the effect of nanoparticles on biochemical pathways and processes of human body.

2. Scientists are primarily concerned about the toxicity, characterization and exposure pathways associated with Nano medicine that might pose a serious threat to the human beings and environment.

3. The societys ethical use of Nano medicine beyond the concerned safety issues, poses a serious question to the researchers.

Read the original post:
Nano Medicine: Meaning, Advantages and Disadvantages

♫ Posted in Nano medicine | | Comments Off»

Nanobiotix a nanomedicine company

♫ Thursday, April 4th, 2019

NANOMEDICINE

FOR BETTER AND LONGER LIFE

Watch our

R&D Day

Experts

Dr. David Raben, MD University of Colorado, Denver, CO, USADr. Tanguy Seiwert, MD University of Chicago Medicine, Chicago, IL, USADr. Colette Shen, MD, PhD University of North Carolina, Chapel Hill, NC, USADr. Jared Weiss, MD University of North Carolina, Chapel Hill, NC, USADr. James Welsh, MD MD Anderson Cancer Center, Houston, TX, USA

APRIL 4, 2019:

NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER

TO RECEIVE EUROPEAN MARKET APPROVAL

NANOXRAY

A FIRST-IN-CLASS RADIOENHANCER

A FIRST-IN-CLASSRADIOENHANCER

WE WORK TO PROVIDE

INNOVATIVE TREATMENTS TO HELP PATIENTS

TO LIVE LONGER AND BETTER.

COLETTE, CLINICAL TEAM

I WORK FOR LIFE.

CLINE, DISCOVERY TEAM

WE FIGHT FOR

MEANINGFUL GOALS TOGETHER.

ALY, FINANCE TEAM

NANOMEDICINE IS MORE THAN EVOLUTION,

ITS A REVOLUTION!

REGIS, MANUFACTURING AND SUPPLY TEAM

ENTHUSIASM,

FAITH IN NANOMEDICINE

AND LOVE FOR INNOVATION!

JULIE, DISCOVERY TEAM

NANOMEDICINEFOR BETTER AND LONGER LIFE

MEET US AT:ESTRO 2019, Milan

QUICK SELECT OR SCROLL DOWN

Continue reading here:
Nanobiotix a nanomedicine company

♫ Posted in Nano medicine | | Comments Off»

Precision medicine and pharmacogenomics – Mayo Clinic

♫ Monday, April 1st, 2019

Precision medicine and pharmacogenomics

Personalized medicine holds the promise that treatments will one day be tailored to your genetic makeup.

Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.

Your age, lifestyle and health all influence your response to medications. But so do your genes. Pharmacogenomics is the study of how a person's unique genetic makeup (genome) influences his or her response to medications.

Precision medicine aims to customize health care, with decisions and treatments tailored to each individual in every way possible. Pharmacogenomics is part of precision medicine.

Although genomic testing is still a relatively new development in drug treatment, this field is rapidly expanding. Currently, more than 200 drugs have label information regarding pharmacogenomic biomarkers some measurable or identifiable genetic information that can be used to individualize the use of a drug.

Each gene provides the blueprint for the production of a certain protein in the body. A particular protein may have an important role in drug treatment for one of several reasons, including the following:

When researchers compare the genomes of people taking the same drug, they may discover that a set of people who share a certain genetic variation also share a common treatment response, such as:

This kind of treatment information is currently used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.

In cancer treatments, there are two genomes that may influence prescribing decisions the genome of the person with cancer (the germline genome) and the genome of the cancerous (malignant) tumor (the somatic genome).

There are many causes of cancer, but most cancers are associated with damaged DNA that allows cells to grow unchecked. The "incorrect" genetic material of the unchecked growth the malignant tumor is really a separate genome that may provide clues for treatment.

One example is thiopurine methyltransferase (TPMT) testing for people who are candidates for thiopurine drug therapy. Thiopurine drugs are used to treat some autoimmune disorders, including Crohn's disease and rheumatoid arthritis, as well as some types of cancer, such as childhood leukemia.

The TPMT enzyme helps break down thiopurine drugs. People who are TPMT deficient don't break down and clear out these drugs quickly enough. As a result, the drug concentration in the body is too high and increases the risk of side effects, such as damage to the bone marrow (hematopoietic toxicity).

Genetic testing can identify people with TPMT deficiency so that their doctors can take steps to reduce the risk of serious side effects by prescribing lower than usual doses of thiopurine drugs or by using other drugs instead.

Although pharmacogenomics has great promise and has made important strides in recent years, it's still in its early stages. Clinical trials are needed not only to identify links between genes and treatment outcomes but also to confirm initial findings, clarify the meaning of these associations and translate them into prescribing guidelines.

Nonetheless, progress in this field points toward a time when pharmacogenomics will be part of routine medical care at least for some drugs.

.

Go here to read the rest:
Precision medicine and pharmacogenomics - Mayo Clinic

♫ Posted in Personalized Medicine | | Comments Off»

Biotechnology – B.S. < Kent State University

♫ Monday, April 1st, 2019

The university affirmatively strives to provide educational opportunities and access to students with varied backgrounds, those with special talents and adult students who graduated from high school three or more years ago.

Freshman Students on the Kent Campus: The freshman admission policy on the Kent Campus is selective. Admission decisions are based upon the following: cumulative grade point average, ACT and/or SAT scores, strength of high school college preparatory curriculum and grade trends. The Admissions Office at the Kent Campus may defer the admission of students who do not meet admissions criteria but who demonstrate areas of promise for successful college study. Deferred applicants may begin their college coursework at one of seven regional campuses of Kent State University. For more information on admissions, including additional requirements for some academic programs, visit the admissions website for new freshmen.

Freshman Students on the Regional Campuses: Kent State campuses at Ashtabula, East Liverpool, Geauga, Salem, Stark, Trumbull and Tuscarawas, as well as the Regional Academic Center in Twinsburg, have open enrollment admission for students who hold a high school diploma, GED or equivalent.

English Language Proficiency Requirements for International Students: All international students must provide proof of English language proficiency (unless they meet specific exceptions) by earning a minimum 525 TOEFL score (71 on the Internet-based version), minimum 75 MELAB score, minimum 6.0 IELTS score or minimum 48 PTE score, or by completing the ESL level 112 Intensive Program. For more information on international admission, visit the Office of Global Educations admission website.

Transfer, Transitioning and Former Students: For more information about admission criteria for transfer, transitioning and former students, please visit the admissions website.

Go here to see the original:
Biotechnology - B.S. < Kent State University

♫ Posted in Biotechnology | | Comments Off»

StemCell Therapy

Archive for April, 2019

What is Stem Cell Therapy – Stem Cell Centers

Personalized Medicine Conferences 2019 | New Zealand 2019 …

Banking Menstrual Stem Cells | What are Menstrual Stem …

Nanomedicine | Ardena

Regenerative Medicine – Tucson Orthopaedic Institute

Regenerative Medicine | NorthShore

Stem Cell Basics VII. | stemcells.nih.gov

Cancers Trick for Dodging the Immune System

Integrative medicine: Alternative becomes mainstream – Mayo …

Benefits of Human Genetic Engineering

Living to 100? Longevity and Genetics Genetic Lifehacks

Biotechnology Careers – Career Path Information | Monster.com

Bone Marrow Stem Cells | NSI Stem Cell

Morristown Ophthalmology – Cataract Surgery NJ

#ACTRIMS2019 Stem Cell Tourism Poses Threat of …

The UK Cystic Fibrosis Gene Therapy Consortium

Nano Medicine: Meaning, Advantages and Disadvantages

Nanobiotix a nanomedicine company

Precision medicine and pharmacogenomics – Mayo Clinic

Biotechnology – B.S. < Kent State University

Categories

Archives

Recommended Sites

Recent Posts